A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
2021
Rituximab is a FDA-approved monoclonal antibody for adults with moderate to severe potentially life-threatening pemphigus vulgaris. Recent studies have focused on assessments of efficacy and safety...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
42
References
2
Citations
NaN
KQI